Acceptability of an annual tenofovir alafenamide implant for HIV prevention in South African women: findings from the CAPRISA 018 Phase I clinical trial

Gengiah, T. N., Heck, C. J., Lewis, L., Mansoor, L. E., Harkoo, I., Myeni, N., Baum, M. M., Moss, J. A., Rooney, J. F., Hankins, C., Pozzetto, B., Abdool Karim, S. S., & Abdool Karim, Q. (2025). Acceptability of an annual tenofovir alafenamide implant for HIV prevention in South African women: findings from the CAPRISA 018 Phase I clinical trial. Journal of the International AIDS Society, 28(2). Portico. https://doi.org/10.1002/jia2.26426
Authors:
Tanuja N Gengiah
Craig J Heck
Lara Lewis
Leila E Mansoor
Ishana Harkoo
Nqobile Myeni
Marc M Baum
John A Moss
James F Rooney
Catherine Hankins
Bruno Pozzetto
Salim S Abdool Karim
Quarraisha Abdool Karim
Affiliated Authors:
Craig J Heck
Salim S Abdool Karim
Quarraisha Abdool Karim
Author Keywords:
acceptability
clinical trial
hiv prevention
implant
prep
tenofovir alafenamide
adenine
alanine
tenofovir
anti-hiv agents
drug implants
placebo
anti human immunodeficiency virus agent
adult
article
clinical article
controlled study
device removal
device safety
drug dose escalation
drug implantation
female
human
human immunodeficiency virus infection
implant removal
pain
patient acceptability
patient attitude
patient compliance
patient experience
phase 1 clinical trial (topic)
pre-exposure prophylaxis
product design
randomized controlled trial (topic)
scar formation
self report
south african
treatment duration
treatment withdrawal
drug implant
drug therapy
middle aged
phase 1 clinical trial
prevention and control
procedures
randomized controlled trial
south africa
young adult
hiv infections
humans
patient acceptance of health care
Publication Type:
Article
Unique ID:
10.1002/jia2.26426
PMID:
Publication Date:
Data Source:
PubMed

Record Created: